Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
As of today, Biogen(BIIB) shares are valued at $244.05. The company's market cap stands at 36.03B, with a P/E ratio of 44.76.
On 2026-10-28, Biogen(BIIB) stock traded between a low of $241.25 and a high of $258.63. Shares are currently priced at $244.05, which is +1.2% above the low and -5.6% below the high.
Biogen(BIIB) shares are trading with a volume of 2.32M, against a daily average of 1.44M.
During the past year, Biogen(BIIB) stock moved between $138.00 at its lowest and $258.78 at its peak.
During the past year, Biogen(BIIB) stock moved between $138.00 at its lowest and $258.78 at its peak.
BIIB News
Biogen reported third quarter 2026 revenue of US$2.80b compared with US$2.53b a year earlier, alongside an adjusted profit of US$2.62 per share that exceeded an...
Biogen (BIIB) shares gained in premarket trading on Wednesday after the Alzheimer's drugmaker reported higher-than-expected Q3 2026 financials thanks mainly to...
Technology Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report Licensing Biogen (BIIB) crushed Wall Street's third-quarter expectations ea...
Analyst ratings
68%
of 37 ratingsMore BIIB News
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The result...
We expect Biogen (BIIB Quick QuoteBIIB - Free Report) to beat expectations when it reports third-quarter 2026 results on Oct. 28, before market open. In t...
Biogen (BIIB) drew fresh attention after its shares rose 5.3%, as traders reacted to positive phase II AMETHYST data for litifilimab in cutaneous lupus and look...
has delivered a strong run over the past year, and the question now is whether the cash it is expected to generate can justify where the stock trades today. Bi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.